Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Daga Shruti |

Präsentationen bei wissenschaftlichen und nicht-wissenschaftlichen Veranstaltungen

Daga, S; Rosenberger, A; Krisper, N; Prietl, B; Reinisch, A; Zebisch, A; Sill, H; Wolfler, A GPR56 and CLL-1 (CLEC12A) as putative leukemic stem cell markers in CD34-positive acute myeloid leukemia
ONCOL RES TREAT. 2018; 41: 73-73. [Poster]
Web of Science

 

Daga, S; Rosenberger, A; Krisper, N; Reinisch, A; Zebisch, A; Sill, H; Wölfler, A GPR56 is a putative marker of leukemic stem cells in CD34-positive acute myeloid leukemia.
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology. 2018; Supplement 1/18: -Annual Meeting of the Austrian Society for Hematology and Medical Oncology; APR, 19-21, 2018; Villach, AUSTRIA. [Poster]

 

Daga, S; Rosenberger, A; Krisper, N; Wölfler, A Limitation of CLL-1 (CLEC12A) as a putative marker of leukemic stem cells in acute myeloid leukemia.
Annual Meeting of the Belgian Hematology Society; FEB 2-3, 2018; Brussels, BELGIUM. 2018. [Poster]

 

Daga, S; Krisper, N; Wölfler, A. GPR56 is a putative leukemic stem cell marker with prognostic significance in acute myeloid leukemia.
9th ÖGMBT Annual Meeting ; SEP 25-27, 2017; Innsbruck, AUSTRIA. 2017. [Poster]

 

Daga, S; Krisper, N; Zebisch, A; Sill, H; Wölfler, A GPR56 is a putative leukemic stem cell marker with prognostic significance in acute myeloid leukemia.
4th International Conference on Acute Myeloid Leukemia; OCT 5-7, 2017; Estoril, PORTUGAL. 2017. [Poster]

 

Gaksch, L; Kashofer, K; Heitzer, E; Daga, S; Hofer, S; Krisper, N; Hofler, G; Zebisch, A; Sill, H; Wolfler, A Persistence of non-DNMT3A mutations predicts relapse in cytogenetically normal AML
ONCOL RES TREAT. 2017; 40: 140-141. [Oral Communication]
Web of Science

 

Gaksch, L; Kashofer, K; Daga, S; Hofer, S; Höfler, G; Zebisch, A; Sill, H; Wölfler A Mutation clearance detected by parallel sequencing at end of treatment: impact on relapse-free survival in intermediate-risk AML patients
memo - Magazine of European Medical Oncology . 2016; 9(1):3-3.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 17-19, 2016; Vienna, AUSTRIA. [Oral Communication]

 

Gaksch, L; Kashofer, K; Heitzer, E; Daga, S; Hofer, S; Krisper, N; Höfler, G; Zebisch, A; Sill, H; Wölfler A Persitence of non-DNMT3A mutations predicts relapse in cytogenetically normal AML.
Oncol Res Treat 2016. 2016; 39(suppl3):140--Jahrestagung DGHO; OCT 14-18,2016; Leipzig. (ISBN: 2296-5270 ) [Oral Communication]
Web of Science

 

© Med Uni Graz • Impressum